Rationale:Mesenteric fibromatosis (MF) is a rare tumor whose biological behavior is intermediate between benign fibrous neoplasms and fibrosarcomas, and the characteristic of these tumors are local aggressive lesions which is prone to local recurrence but non-metastasizing. The common symptom is abdominal distention or painless mass. We report a case of giant MF in abdominal cavity with abdominal distention as the main symptom.Patient concerns:A 26-year-old male presented with 2-month history of abdominal distention, lack of appetite, and symptoms grew progressively more debilitating with time.Diagnoses:This patient underwent a contrast-enhanced computed tomography scan which showed a giant (37 × 25 × 13 cm), inhomogeneous enhancing, well-defined, and soft tissue density mass in abdominal cavity, possibly arising in mesocolon, which suggested a high possibility of MF. The postoperative pathology showed that the tumor cells to be positive for β-catenin, vimentin, negative for CD34, CD117, DOG-1, S-100, Desmin, which confirmed the diagnosis of MF.Interventions:Exploratory laparotomy was performed, which revealed a large mass involving the transverse colon wall, the root of mesocolon, and encasing the middle colic vessels and the 1st branch of jejunal arteries. The complete surgical resection was performed and the mass weighted 10 kilograms (kg).Outcomes:The patient recovered uneventfully and was discharged 9 days after surgery. Three-month, 6-month, 12-month and 18-month on follow-up after surgery, showed no evidence of recurrence.Lessons:The MF is a very rare tumor, especially a giant tumor (10 kg) involving the muscular layer of colon wall. In addition, treatment of giant MF still remains a challenge. We consider that surgical resection with negative margins is the goal but not at the expense of damaging the function of vital organs. Specific measures should be considered based on the individual patient in order to relieve symptoms and improve quality of life.

No abstract

Background Modified Xiaochengqi Decoction is a new prescription designed by the author to add astragalus, frankincense and myrrh on the basis of the classic Xiaochengqi Decoction based on the characteristics of biliary tract surgery, and it has been used for clinical differentiation.Therefore, in order to evaluate the clinical effect of Modified Xiaochengqi Decoction in perioperative period of cholelithiasis, this study conducted a prospective randomized controlled study. Methods A total of 162 patients with cholelithiasis were randomly divided into three groups. Modified Xiaochengqi Decoction group: ERAS process + Modified Xiaochengqi decoction. Xiaochengqi Decoction group: ERAS process + Xiaochengqi decoction. Control group: ERAS process + warm boiled water 50ml.Compare the clinical indicators, immune indicators and acute inflammatory stress response indicators between the three groups, and observe the adverse reactions of traditional Chinese medicine. Results Clinical indicators In the Modified Xiaochengqi Decoction group, the postoperative VAS pain scores was decreased, the postoperative activity time and activity distance was increased, the feeding time was advanced, the recovery of gastrointestinal function was advanced, the postoperative cost and postoperative hospital stay was reduced and the incidence of nausea and vomiting was reduced (P <0.05).There was no serious adverse reaction in Modified Xiaochengqi Decoction. Immune indicators On the 1st and 2nd day after operation, the expression of CD3+,CD4+,CD19+ and the ratio of CD4 + / CD8 + in the Modified Xiaochengqi Decoction group was higher than that in the Xiaochengqi Decoction group and the control group.The expression of CD8+ and NK cell was not statistically different between the three groups (P>0.05). A cute inflammatory stress response indicators On the 1st and 2nd day after the operation, the expression of IL-6, CRP and SAA in the Modified Xiaochengqi Decoction group was lower than that in the control group, and the expression of substance P was higher than that in the control group (P<0.05).There was no significant difference in IL-10 expression between the three groups (P>0.05). Conclusions Modified Xiaochengqi Decoction relieved the inflammatory response and improved the immune function in the perioperative period, and promoted postoperative rehabilitation. Moreover, there was no serious adverse reaction in Modified Xiaochengqi Decoction.Trial registration This study is registered at Chinese Clinical Trial Registry.The registration identification number is ChiCTR2000033125.Registered 25 May 2015 Retrospectivelyregistered,http://www.medresman.org.cn/ChiCTR2000033125.